Medicus completed a randomized, double-blind Phase 2 study (SKNJCT-003) in 90 nodular basal cell carcinoma patients, comparing two doxorubicin dose levels via microneedle delivery against a device-only control. The 200 µg cohort achieved up to 73% clinical clearance by Day 57, indicating durable responses and potential to reduce immediate surgery.

Teverelix®, a next-generation GnRH antagonist targeting high-risk advanced prostate cancer and acute urinary retention, is advancing into a 390-patient Phase 2b study. The program also explores symptomatic endometriosis using biomarker-driven stratification, addressing an estimated $6 billion market opportunity and reducing future royalties to ~2%.

In 2025, the company secured $31.9 million in financing and ended the year with $8.7 million in cash versus $4.2 million in 2024. Operating expenses totaled $34.4 million, net loss reached $35.4 million (up from $11.2 million), and the firm acknowledged substantial doubt about its ability to continue without further funding.

Upcoming milestones include an end-of-Phase 2 FDA meeting for SkinJect® to define a 505(b)(2) pathway, initiation of Phase 2b Teverelix trials, a Gorlin Syndrome expanded access IND, and expansion of AI-driven trial design in collaboration with HelixNano and Reliant AI to accelerate and de-risk clinical programs.